GlucoTrack, Inc. (GCTK)
NASDAQ: GCTK · Real-Time Price · USD
0.374
-0.026 (-6.45%)
At close: Feb 21, 2025, 4:00 PM
0.368
-0.006 (-1.58%)
After-hours: Feb 21, 2025, 7:59 PM EST
GlucoTrack Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
3.88M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GCTK News
- 18 days ago - Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering - GlobeNewsWire
- 19 days ago - Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor - GlobeNewsWire
- 25 days ago - Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - Glucotrack Announces ISO 13485:2016 Certification - GlobeNewsWire
- 5 weeks ago - Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs - GlobeNewsWire
- 6 weeks ago - Glucotrack to Present at TechBio Showcase™ 2025 - GlobeNewsWire
- 2 months ago - GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR - GlobeNewsWire
- 3 months ago - Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt - GlobeNewsWire